Home โบ Lymphoma
Lymphoma clinical trials recruiting in the U.S.
141 studies for Lymphoma are recruiting participants at sites across the United States.
Lymphoma is a cancer affecting the immune system. Hodgkins Lymphoma and Non Hodgkins Lymphoma are types of lymphoma. Learn about symptoms and treatments.
Cities with the most studies
- Houston, TX34 studies
- Boston, MA33 studies
- New York City, NY33 studies
- Washington, DC23 studies
- Chicago, IL20 studies
- Baldwin Park, CA20 studies
- Durham, NC17 studies
- Philadelphia, PA15 studies
- St. Louis, MO15 studies
- Cleveland, OH13 studies
- Seattle, WA12 studies
- Edison, NJ12 studies
- Columbus, OH11 studies
- Atlanta, GA11 studies
- Nashville, TN11 studies
- Rochester, MN11 studies
- Miami, FL11 studies
- Salt Lake City, UT10 studies
- Pittsburgh, PA10 studies
- Dallas, TX10 studies
- Los Angeles, CA10 studies
- Queens, NY10 studies
- Mountain View, CA9 studies
- Denver, CO9 studies
- Milwaukee, WI9 studies
- Greenburgh, NY9 studies
- Cincinnati, OH8 studies
- Birmingham, AL8 studies
- Staten Island, NY8 studies
- East Norwalk, CT8 studies
- Aurora, CO8 studies
- Portland, OR8 studies
- Omaha, NE7 studies
- San Antonio, TX7 studies
- New Rochelle, NY7 studies
- New Haven, CT7 studies
- Tampa, FL7 studies
- Phoenix, AZ7 studies
- San Francisco, CA6 studies
- Cedar Rapids, IA6 studies
By state
- Alabama9 studies
- Arizona11 studies
- Arkansas3 studies
- California39 studies
- Colorado16 studies
- Connecticut7 studies
- District of Columbia7 studies
- Florida25 studies
- Georgia15 studies
- Illinois23 studies
- Indiana6 studies
- Iowa6 studies
- Kansas7 studies
- Kentucky5 studies
- Maryland21 studies
- Massachusetts33 studies
- Michigan12 studies
- Minnesota14 studies
- Missouri17 studies
- Nebraska7 studies
- New Jersey18 studies
- New York42 studies
- North Carolina22 studies
- Ohio28 studies
- Oklahoma4 studies
- Oregon8 studies
- Pennsylvania24 studies
- South Carolina4 studies
- Tennessee15 studies
- Texas45 studies
- Utah13 studies
- Virginia10 studies
- Washington12 studies
- Wisconsin12 studies
Recently updated studies
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Recruiting
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07013435Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Recruiting
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07014293Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT00923507Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RecruitingObservational study
Ages 3 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT01441089Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
RecruitingObservational study
Ages 18 to 120 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT00006518Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 120 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT03223610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
24 Months โ 18 Years ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06441331Epco, Zanu, Ritux for R/R FL or MZL
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06563596Rutgers University Study of the Genetics of Blood Cancers
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 110 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07714044A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
Up to age 25 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT04094610CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RecruitingPhase 2
Ages 18 to 99 ยท All sexes ยท Updated Sep 24, 2026 ยท NCT04083495Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06398457Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT02974647Precise Oncology Interventions in Nutrition and Training (OnPoint)
RecruitingHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT06534918A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT07015242Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT04301076Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
RecruitingPhase 2
Ages 12 and older ยท All sexes ยท Updated Sep 22, 2026 ยท NCT03258567A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 17, 2026 ยท NCT07221500Collection of Tissue Samples for Cancer Research
RecruitingObservational study
2 Months ยท All sexes ยท Updated Sep 16, 2026 ยท NCT00900198Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RecruitingPhase 1
Ages 18 to 100 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RecruitingPhase 1/2
Ages 12 and older ยท All sexes ยท Updated Sep 14, 2026 ยท NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RecruitingPhase 1/2
12 Months โ 21 Years ยท All sexes ยท Updated Sep 11, 2026 ยท NCT04870944A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 8, 2026 ยท NCT06624085Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RecruitingPhase 3
Ages 18 to 18 ยท All sexes ยท Updated Sep 8, 2026 ยท NCT07509151From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.